Francesco Lo-Coco, MD, Hematology, University Tor Vergata, speaks at the 2012 American Society of Hematology annual meeting about the use of arsenic trioxide in acute promyelocytic leukemia.
Francesco Lo-Coco, MD, Hematology, University Tor Vergata, speaks at the 2012 American Society of Hematology annual meeting about the use of arsenic trioxide (ATO) in acute promyelocytic leukemia (APL).
Currently, all-trans retinoic acid (ATRA) plus chemotherapy is the gold standard for newly diagnosed APL patients demonstrating an 80% cure rate and typical toxicities (myelosuppression infections, hair loss). In the past 10 to 15 years, Lo-Coco says, ATO was suggested by Chinese investigators to show efficacy in APL with inferior toxicity.
A phase III trial analyzing ATRA and ATO versus ATRA and idarubicin (AIDA) in newly diagnosed, non high-risk APL showed that the new strategy is at least equally effective.
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More